LCM
ZBIO

Landscape Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Landscape Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,074
Closed -$170K – 942
2024
Q3 		$170K Buy
+10,074
New +$181K 0.02% 582

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Landscape Capital Management's ZBIO Position: Q4 2024 in Review

Landscape Capital Management sold out of Zenas BioPharma (ZBIO) in Q4 2024, closing a stake of 10,074 shares — an estimated $170K sold.

Landscape Capital Management first reported a position in ZBIO in Q3 2024 and held it in 1 quarter. The position peaked at $170K in Q3 2024. 65 funds tracked by Wall St. Rank hold ZBIO as of Q4 2024.

  • Landscape Capital Management reported no remaining Zenas BioPharma position as of Q4 2024 after selling out during the quarter.
  • Landscape Capital Management sold 10,074 Zenas BioPharma shares in Q4 2024, an estimated $170K.
  • Landscape Capital Management first reported a position in Zenas BioPharma in Q3 2024 and held it in 1 quarter.
  • Landscape Capital Management's Zenas BioPharma position peaked at $170K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Zenas BioPharma as of Q4 2024.

Based on Landscape Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.